Amivantamab Plus Lazertinib Combo Show Promising Results at ESMO 2020
By DocWire News Editors - Last Updated: September 21, 2023DocWire News interviews Dr. Joshua Sabari, of the Perlmutter Cancer Center at NYU Langone Health, about recent results of the CHRYSALIS study presented at the ESMO 2020 conference.
Advertisement
The CHRYSALIS study evaluated the patient response rate of the human bispecific antibody amivantamab in combination with an EGFR tyrosine kinase inhibitor lazertinib in patients with non-small cell lung cancer.
Read a press release about the study here.
Advertisement
Related Posts
Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
The accelerated approval is specifically for patients with high c-Met protein overexpression.
The phase 2 platform study has been assessing the combination of belrestotug plus dostarlimab in NSCLC.
Researchers synthesized circular RNA encoding NY-ESO-1, which is expressed in a proportion of patients with NSCLC.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.